STOCK TITAN

Relay Therapeutics (RLAY) SEC Filings, Jul-Aug 2026

RLAY NASDAQ

Relay Therapeutics, Inc. filings document the regulatory record of a clinical-stage precision-medicine company developing small molecule programs for cancer and genetic disease. Form 8-K reports include operating and financial results, Regulation FD clinical updates for zovegalisib, FDA Breakthrough Therapy designation disclosure, material agreements, capital-structure matters, and governance changes.

Proxy materials describe board composition, committee structure, executive compensation, equity awards, shareholder voting matters, and related governance policies. Other filings address amendments to bylaws, including exclusive-forum provisions, and securities disclosures tied to RLAY common stock and its development-stage pipeline.

Rhea-AI Summary

FMR LLC reported beneficial ownership of 20,015,113.24 shares of Relay Therapeutics, Inc. common stock on a Schedule 13G, representing 9.4% of the class as of June 30, 2026. FMR has sole voting power over 19,967,458 shares and sole dispositive power over 20,015,113.24 shares, with no shared voting or dispositive power.

Abigail P. Johnson is listed as a reporting person with sole dispositive power over the same 20,015,113.24 shares and a 9.4% beneficial ownership of the class. One or more other persons have rights to receive dividends or sale proceeds from these securities, but no such person holds more than 5% of the outstanding common stock. FMR files as a parent holding company, with relevant subsidiaries identified in an attached Exhibit 99.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
ownership
-
Rhea-AI Summary

RLAY insider Sekar Kathiresan filed to sell common stock under a planned transaction. The filing lists 42,225 shares of common stock to be sold on 08/04/2026 in connection with a stock option exercise, with an indicated value of $826,465.70, to be executed in cash through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. It also reports prior sales over the past three months: 30,000 shares on 07/31/2026 for $563,553.00, 30,000 shares on 07/21/2026 for $594,414.00, and 66,055 shares on 07/20/2026 for $1,293,555.07.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
other
-
Rhea-AI Summary

RLAY reporting person Sekar Kathiresan filed to sell common stock. The planned transaction covers 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on or about July 31, 2026 on NASDAQ, with an indicated value of $563,553.00.

The filing also lists prior sales within three months: 30,000 shares of common stock on July 21, 2026 for $594,414.00, and 66,055 shares on July 20, 2026 for $1,293,555.07. The planned sale is linked to a stock option exercise settled in cash.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
other
Rhea-AI Summary

Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported the sale of 1,459 shares of common stock on July 28, 2026 at $18.61 per share. The shares were sold solely to cover income tax withholding from the vesting of 3,269 RSUs, with no discretion by the officer and in line with company policies. After the sale, he beneficially owns 158,285 shares, including 6,538 shares underlying RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics, Inc. officer Peter Rahmer, Chief Corporate Development Officer, had 748 shares of common stock sold on July 28, 2026 at $18.61 per share to cover income tax withholding from the vesting of 3,051 RSUs. He had 228,165 shares remaining afterward, including 6,102 shares underlying RSUs, and no discretion over the tax-related sale, which followed the company’s RSU vesting policies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
insider
-
Rhea-AI Summary

Relay Therapeutics, Inc. executive Donald A. Bergstrom, President of R&D, reported the sale of 2,237 shares of common stock on July 28, 2026 at $18.61 per share. The sale covered income tax withholding on the vesting of 5,012 RSUs on July 27, 2026. After the transaction, he directly held 407,660 shares, including 10,025 shares underlying RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
insider
Rhea-AI Summary

Relay Therapeutics insider Sekar Kathiresan filed a notice to sell company stock. The filing covers a proposed sale of 30,000 shares of common stock of Relay Therapeutics through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $594,414.00, expected on July 21, 2026. The shares are tied to a stock option exercise by the issuer for cash. The filing also reports that, during the past three months, 66,055 shares of common stock were sold on July 20, 2026 for total proceeds of $1,293,555.07.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
other
-
Rhea-AI Summary

Relay Therapeutics, Inc. director Sekar Kathiresan filed a notice of a proposed sale of 66,055 common shares, with an aggregate market value of $1,293,555.07 and an approximate sale date of July 20, 2026. The notice says the shares were acquired from the issuer through a stock option exercise on July 20, 2026, with cash payment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
other
-
Rhea-AI Summary

Relay Therapeutics’ President of R&D, Donald A. Bergstrom, reported an open-market sale of 8,660 shares of common stock at a weighted average price of $18.71 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he directly holds 409,897 shares, including 15,037 shares underlying restricted stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
insider
Rhea-AI Summary

Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported routine equity activity involving company common stock. On June 30, 2026, he acquired 3,056 shares through the company’s Employee Stock Purchase Plan at $6.95 per share, a plan-based purchase described as exempt under Rule 16b-3.

On July 7, 2026, he sold 48,199 shares of common stock in an open-market transaction at a weighted average price of $19.58 per share, executed in multiple trades between $18.52 and $20.20 pursuant to a pre-established Rule 10b5-1 trading plan adopted on October 30, 2025. Following these transactions, Patel directly holds 615,898 shares of Relay Therapeutics common stock.

Separate from his direct holdings, irrevocable trusts for the benefit of his family members hold 687,355 shares and 199,548 shares of common stock, respectively, with an independent trustee. Patel disclaims beneficial ownership of the shares held in these trusts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
insider

FAQ

How many Relay Therapeutics (RLAY) SEC filings are available on StockTitan?

StockTitan tracks 114 SEC filings for Relay Therapeutics (RLAY), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Relay Therapeutics (RLAY)?

The most recent SEC filing for Relay Therapeutics (RLAY) was filed on November 20, 2026.